| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
a National Cancer Institute, Bethesda, Maryland, USA; b All Ireland Fatigue Coalition, c Queens University Belfast, and d Belfast City Hospital, Belfast, Northern Ireland
Correspondence: Gregory Curt, M.D., The Oncologist, 1 Prestige Place, Miamisburg, Ohio 45342, USA. Telephone: 937-291-2355; Fax: 937-291-4229; Gcurt{at}TheOncologist.com
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
| STATE OF THE SCIENCE |
|---|
|
|
|---|
|
The disparity between the state of the science and the magnitude of the problem was recently recognized at the U.S. National Institutes of Health (NIH) during the July 2002 State-of-the-Science Conference on Symptom Management in Cancer: Pain, Depression, and Fatigue. The consensus conference brought together national experts in the areas of palliative care and symptom management to address key questions regarding the occurrence, assessment, and treatment of fatigue symptoms; barriers to effective treatment; and directions for future research in the area. The panel called for more resources to be devoted to studying the occurrence, causes, and impediments to effective treatments of fatigue symptoms [2].
The panel enumerated potential treatments drawn from the worlds literature.
They noted two interventions that appear to have some benefit in treating fatigue. There is some evidence, based primarily on observation in nursing literature, that exercise interventions are of benefit in women with breast cancer. The panel noted that this intervention had not been adequately studied. They also noted that erythropoietin alpha can be effective as an intervention for treating chemotherapy-related anemia and its related fatigue. These two observations are the sum total of what we know today about the management of cancer-related fatigue.
The panel made important recommendations, some of which are prescient in light of the goals of the AIFC. The first recommendation is somewhat generic: that new treatments for fatigue should be developed and evaluated. But the next two recommendations go to the heart of what the AIFC is doing. Recognizing that both pharmacologic and nonpharmacologic treatments can be useful in the management of cancer-related fatigue, the panel suggested that studies be designed and implemented to investigate the effectiveness of both the combinations and sequencing of pharmacologic and nonpharmacologic interventions in managing cancer-related fatigue.
Another of the panels recommendations was to support public-private partnerships among academia, government, and business to implement fatigue research. This is precisely what the AIFC represents. The AIFC is the first publicprivate partnership to be sponsored as part of the Ireland-Northern Ireland-National Cancer Institute Cancer Consortium, a consortium operating under a Memorandum of Understanding signed by the health ministers of Ireland and Northern Ireland and the Secretary of Health and Human Services of the U.S.
The final recommendation of the panel was to investigate the relationship between symptom management and adherence to cancer treatment. That is, if cancer-related fatigue is carefully monitored and managed, will patients adhere to protocol medicine better and have better treatment outcomes [3]?
| U.S. FATIGUE COALITION SURVEYS |
|---|
|
|
|---|
The U.S. Fatigue Coalition conducted two surveys to understand the incidence, prevalence, and functional consequences of fatigue for patients with cancer. Fatigue 1, published in 1997, was a telephone survey designed to determine the perceptions of patients and oncologists regarding the impact of fatigue [4]. The database was very large; 375,000 families agreed to be interviewed by telephone, and 419 patients, 200 caregivers, and 197 oncologists were actually contacted. In Fatigue 2, the objective was to confirm the prevalence demonstrated in Fatigue 1 and to assess the emotional, social, physical, and economic impacts of cancer-related fatigue and the duration of cancer-related fatigue as well [5]. This survey was restricted to patients; oncologists and caregivers were not part of the survey.
Both studies had the same weakness, even though they were peer-reviewed and published. This weakness involves the time lapse between treatment and the survey. In Fatigue 1, approximately half of the patients (49%) had been treated more than 1 year prior to being interviewed by telephone. Fatigue 2 had an even greater time disparity in that 60% of patients were recalling their cancer-related fatigue on the telephone 2 years to more than 5 years after treatment.
| AIFC SURVEY |
|---|
|
|
|---|
In addition, the AIFC survey is likely to have a greater population base. The projected accrual onto this study is 1,000 patients, as opposed to the earlier, smaller studies. This larger base will allow more robust statistical analyses of the data. A unique feature of the surveys conducted in Ireland is that these will capture data from a significant proportion of caregivers. This is truly a national survey, which would be very difficult, if not impossible, to do in a place as large as the U.S. For that reason, it will be useful to government agencies both in Northern Ireland and in the Republic of Ireland for determining priorities in research and clinical care for the future.
| SURVEY FINDINGS |
|---|
|
|
|---|
|
The surveys have addressed the difficulties that fatigue creates for cancer patients, with an emphasis on the physical constraints, the emotional effects, and the psychological toll of cancer-related fatigue. These difficulties were very similar in both the Irish and U.S. populations. Perhaps the most remarkable finding is the proportion of those who have cancer-related fatigue so severely that they say they have an urge to die; 19% of U.S. patients and, so far, 10% of Irish patients have made such comments. Clearly, this is not the common fatigue of everyday life.
One area of difference that may have an impact on the AIFC is the answer to the question, "With whom do you discuss your cancer fatigue?" Overwhelmingly, U.S. patients talked to their physician (79%); far fewer (28%) spoke to their nurse. In Ireland, the participation of the nurse and the oncologist is much more balanced: 46% of Irish patients discussed their cancer-related fatigue with their physician, and 44% discussed it with their nurse. Another important point, suggested by the data gathered to date, is that Irish patients were much more likely not to discuss their fatigue with anyone. Twenty-six percent of patients in Ireland did not discuss their cancer fatigue with anyone, compared with 8% of patients in the U.S.
Irish and U.S. physicians were similar in their response to cancer-related fatigue. In the U.S., physicians either did nothing or prescribed rest 77% of the time; in Ireland physicians did likewise 87% of the time. The use of diet or nutrition, prescription drugs, and exercise was not a common practice in either country.
In order to define the economic impact of cancer-related fatigue, the Fatigue 2 survey also addressed patient employment status at the time of cancer diagnosis. There appear to be some differences between the U.S. and Irish populations. Patients were almost twice as likely to be working full time in the U.S. Irish patients were more likely to be self-employed or retired. Overall, 59% of U.S. patients and 36% of Irish patients were actively working at the time of diagnosis. However, the impact of cancer-related fatigue on Irish patients was greater (Table 2
).
|
| RECOMMENDATIONS FOR THE FUTURE |
|---|
|
|
|---|
Expanding public awareness will be a very important part of the AIFCs strategic plan. Publishing survey results in multiple venues to reach medical oncologists, oncology nurses, and patient advocates will be important. In the U.S., awareness-building programs have been very useful. The Oncology Nursing Society in the U.S. sponsored a Fatigue Day with a toll-free number that patients could call to discuss cancer-related fatigue. Educational seminars and a virtual reality exhibit created by Ortho Biotech have allowed health care providers to put themselves in a patients shoes and learn what it is like to have cancer-related fatigue.
Establishing cancer-related fatigue as a medical condition by developing guidelines for diagnosis and treatment is also key. As multidisciplinary treatment centers develop, there will be resonant expertise. The overall goal of this effort, now a year old, is to improve the quality of life for patients with cancer in Ireland. But there is a greater vision at stake here, too: to provide the blueprint for expanding awareness, research, and patient care elsewhere.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
A. Sood, D. L. Barton, B. A. Bauer, and C. L. Loprinzi A Critical Review of Complementary Therapies for Cancer-Related Fatigue Integr Cancer Ther, March 1, 2007; 6(1): 8 - 13. [Abstract] [PDF] |
||||
![]() |
P. Poirier Policy Implications of the Relationship of Sick Leave Benefits, Individual Characteristics, and Fatigue to Employment During Radiation Therapy for Cancer Policy Politics Nursing Practice, November 1, 2005; 6(4): 305 - 318. [Abstract] [PDF] |
||||
![]() |
K. D. Phillips, R. L. Sowell, M. Rojas, A. Tavakoli, L. J. Fulk, and G. A. Hand Physiological and Psychological Correlates of Fatigue in HIV Disease Biol Res Nurs, July 1, 2004; 6(1): 59 - 74. [Abstract] [PDF] |
||||
![]() |
P. A. Daly Introduction: All Ireland Fatigue Coalition Oncologist, February 1, 2003; 8(90001): 1 - 2. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |